This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Estee Lauder, Stryker, Accenture, Cisco and Costco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Stryker, Accenture, Cisco and Costco
Amedisys Closes Oklahoma-Based RoseRock Healthcare Buyout
by Sriparna Ghosal
The acquisition of RoseRock Healthcare aligns with Amedisys' (AMED) strategy of foraying into the hospice care market of Oklahoma.
3 Reasons Why Investors Should Retain PerkinElmer (PKI) Stock
by Zacks Equity Research
PerkinElmer (PKI) has been gaining investor confidence on consistently positive results.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.
Globus Medical Global Base Solid, Pricing Scenario Bothers
by Zacks Equity Research
Globus Medical (GMED) is upbeat about its growth prospects in the current and the emerging global markets through a continual expansion of direct and distributor sales forces.
5 Excellent Blue-Chip Stocks for Q2
by Swarup Gupta
With their large capital base and strong reputation, blue-chips may prove to be the best option for investors.
Neogen Hurt by Weakness in Animal Safety, Currency Woes
by Zacks Equity Research
Neogen (NEOG) exits fiscal third quarter on a disappointing note due to poor performance of Animal Safety segment.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
STERIS (STE) has been gaining investors' confidence on consistently positive results.
Myriad Genetics Gains on Innovation, New Reimbursements
by Zacks Equity Research
Myriad Genetics (MYGN) aims at raising revenues by commercializing its product suite that includes Vectra DA, Prolaris, myPath Melanoma, Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test.
ResMed (RMD) Introduces ReSupply Solution, Expands in HME
by Zacks Equity Research
ResMed (RMD) claims ReSupply solution to improve patient response through growth in the long-term therapy adherence of those suffering sleep apnea.
Baxter Showcases PN Product Portfolio at ASPEN Conference
by Zacks Equity Research
The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.
Bruker Consistently Gains From NANO & New Strategic Buyouts
by Zacks Equity Research
Bruker (BRKR) is progressing well with its three strategic buyouts, indicative of a majority interest in both Hain Diagnostics and Mestrelab along with the Alicona Imaging acquisition.
Medtronic Unveils MedTech Innovation Accelerator in China
by Zacks Equity Research
The MedTech Innovation Accelerator is a collaborative initiative on part of Medtronic (MDT) to foray into the Chinese med-tech innovation market via venture investments, incubation and acceleration.
Masimo Gets FDA Clearance for Rad-67 Monitoring Device
by Zacks Equity Research
The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.
Baxter (BAX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results
by Zacks Equity Research
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
3 Reasons Growth Investors Will Love Stryker (SYK)
by Zacks Equity Research
Stryker (SYK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Stryker (SYK) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth-driving factor for Stryker (SYK) in the past year has been increasing net sales from each of its three major business segments.
Stryker (SYK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Stryker (SYK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
7 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Intuitive Surgical da Vinci SP Gets FDA Nod, Prospects Bright
by Zacks Equity Research
Intuitive Surgical (ISRG) fortifies its foothold in the global robotic-surgery market.
Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg
by Zacks Equity Research
Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) makes a few lucrative acquisitions in recent times.
Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) solid domestic and international performance aids Q4 results.
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.